Bronchiolitis in Infants: A Practical Guide to Diagnosis and Supportive Management
Clinical Practice Update — Clinical Diagnosis, Severity Assessment, Supportive Care, Therapies to Avoid, and Safe Discharge in Infants (AAP: 1–23 Months; CPS/NICE: Up to 24 Months)
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Clinical diagnosis of bronchiolitis, severity assessment, supportive care (oxygen, hydration, minimal handling), interventions that should not be used routinely, high-flow nasal cannula therapy, and safe discharge planning
- Target Audience
- General paediatricians, emergency physicians, family physicians, paediatric nurses, residents, nurse practitioners
- Setting
- Emergency departments, inpatient paediatric wards, primary care, intensive care
- Source Evidence
- •AAP Clinical Practice Guideline — Diagnosis, Management, and Prevention of Bronchiolitis (Pediatrics, 2014)
- •NICE NG9 — Bronchiolitis in Children: Diagnosis and Management (updated August 2021)
- •CPS Position Statement — Bronchiolitis: Recommendations for Diagnosis, Monitoring and Management of Children 1–24 Months (updated 2021)
- •Australasian Bronchiolitis Guideline: 2025 Update (PREDICT Network, J Paediatr Child Health, 2025)
Key Clinical Takeaways
The central message of bronchiolitis management has not changed in a decade: less is more. Supportive care remains the only intervention with proven benefit. The challenge lies in resisting pressure to “do something” beyond what the evidence supports.
- 1Diagnose bronchiolitis clinically — history and physical examination are sufficient; routine chest X-rays and RSV swabs are not needed → Diagnosis
- 2Identify high-risk infants early: age under 12 weeks, prematurity, congenital heart disease, chronic lung disease, and immunodeficiency all increase the risk of severe disease → Risk Factors
- 3The mainstays of treatment are supplemental oxygen (based on guideline-specific SpO2 thresholds, generally ≤90–92%), hydration support, and gentle nasal suctioning — nothing more is routinely needed → Supportive Care
- 4Do not prescribe bronchodilators, corticosteroids, antibiotics, or chest physiotherapy — none of these improve outcomes in bronchiolitis and all carry risks → What Not to Do
- 5High-flow nasal cannula (HFNC) is an option for infants who remain hypoxic despite standard low-flow oxygen, but it has not been shown to reduce ICU admission → Respiratory Support
- 6Consider using intermittent rather than continuous pulse oximetry in stable, non-hypoxic infants — continuous monitoring prolongs hospitalisation without improving safety → Monitoring
- 7Educate families that bronchiolitis typically worsens over days 3–5 before improving — set clear expectations and red-flag safety netting at discharge → Discharge
- 8Encourage exclusive breastfeeding and tobacco smoke avoidance as primary prevention measures → Prevention
- 9RSV prevention is evolving rapidly — nirsevimab and maternal RSV vaccination are now recommended for eligible infants → RSV Prophylaxis
How Should You Diagnose Bronchiolitis?
Bronchiolitis is a clinical diagnosis. It presents as a viral upper respiratory prodrome (rhinorrhoea, cough, low-grade fever) followed by increased respiratory effort and wheeze or crackles in an infant aged 1–24 months. The diagnosis does not require — and should not routinely involve — imaging or laboratory testing.
History and physical examination are all that is needed to diagnose bronchiolitis and gauge its severity — no further workup is routinely required. The classic presentation combines a coryzal prodrome with cough, tachypnoea, chest recession, wheeze or crackles, and feeding difficulty in an infant under 2 years during the respiratory virus season.
Strong Rec Moderate Evidence AAP 2014 NICE 2021Routine chest radiographs and blood tests add no value in typical bronchiolitis. Chest X-rays frequently show non-specific changes (hyperinflation, atelectasis) that are misinterpreted as bacterial pneumonia, leading to unnecessary antibiotic prescribing.
Strong Rec Moderate Evidence AAP 2014 Australasian 2025Routine viral testing (including RSV swabs) is unnecessary because knowing the causative virus does not change management. RSV testing is appropriate only if the result would alter infection control decisions (e.g., cohorting) or if an infant receiving palivizumab prophylaxis is admitted.
Strong Rec Moderate Evidence AAP 2014Assess risk factors for severe disease at presentation: age under 12 weeks, gestational age under 37 weeks, haemodynamically significant congenital heart disease, chronic lung disease of prematurity, immunodeficiency, and neuromuscular disorders. These factors should lower the threshold for admission and closer monitoring.
Moderate Rec Moderate Evidence AAP 2014 NICE 2021 CPS 2021What Should You NOT Prescribe?
This is arguably the most important section of this article. The evidence against multiple commonly used therapies in bronchiolitis is robust and consistent across all major guidelines. Knowing what to withhold is as critical as knowing what to give.
There is no role for salbutamol (albuterol) in bronchiolitis. Multiple large RCTs and meta-analyses show no clinically meaningful benefit. Bronchiolitis involves inflammation and oedema of the small airways, not the bronchospasm that beta-agonists target.
Against High Evidence AAP 2014 NICE 2021 CPS 2021 Australasian 2025Nebulised adrenaline (epinephrine) should not be part of routine management. While some ED-based studies showed short-term clinical score improvement, no consistent reduction in hospitalisation or disease duration has been demonstrated.
Against Moderate Evidence AAP 2014 NICE 2021 Australasian 2025Systemic corticosteroids (oral or intravenous) have no place in bronchiolitis management in any setting. They do not reduce admission rates, length of stay, or clinical severity scores, and they expose infants to unnecessary side effects without benefit.
Against High Evidence AAP 2014 NICE 2021 CPS 2021Antibiotics are not indicated unless there is a confirmed or strongly suspected concomitant bacterial infection. The rate of concurrent serious bacterial infection in bronchiolitis is very low. A secondary fever spike after initial improvement, or a toxic-appearing infant, should prompt reconsideration.
Strong Rec Moderate Evidence AAP 2014 NICE 2021Chest physiotherapy has no role in bronchiolitis. It does not improve clinical outcomes and may distress an already struggling infant.
Against Moderate Evidence AAP 2014 NICE 2021Interventions to Avoid in Bronchiolitis: Why Each One Fails
| Intervention | Why It Seems Logical | Why the Evidence Says No | The Harm of Doing It Anyway |
|---|---|---|---|
| Salbutamol | The infant is wheezy, so it must be bronchospasm | Wheeze in bronchiolitis is from mucosal oedema and mucus plugging, not smooth muscle spasm; RCTs show no benefit | Tachycardia, tremor, delays discharge, reinforces a false asthma diagnosis |
| Corticosteroids | Steroids reduce airway inflammation in asthma and croup | The inflammatory pathway in bronchiolitis does not respond to corticosteroids; multiple large trials show zero benefit | Immunosuppression in a virally infected infant, hyperglycaemia, unnecessary cost |
| Antibiotics | The CXR shows an “infiltrate” | The infiltrate is almost always atelectasis; the rate of concurrent bacterial infection is very low | Antimicrobial resistance, side effects, cost, parental expectation of antibiotics for future episodes |
| Chest physio | Help clear secretions from the small airways | Cochrane review shows no reduction in length of stay, oxygen requirement, or severity score | Distresses an already tachypnoeic infant; increases energy expenditure |
| Routine CXR | Rule out pneumonia or other pathology | Atelectasis mimics consolidation on CXR; imaging increases antibiotic use without benefit | Radiation exposure, unnecessary antibiotics, delayed discharge, increased cost |
| Ipratropium bromide | Anticholinergic effect may dry secretions | No evidence of benefit in bronchiolitis; explicitly listed by NICE as “do not use” | Side effects without clinical benefit; unnecessary cost |
| Montelukast | Leukotriene receptor antagonist used in asthma | No evidence of benefit in acute bronchiolitis; explicitly listed by NICE as “do not use” | Unnecessary medication exposure and cost |
What Actually Works? Supportive Care
Bronchiolitis is self-limiting. The role of the clinician is to support the infant through the peak of illness (typically days 3–5) while monitoring for deterioration. The three pillars of supportive care are oxygen supplementation when needed, hydration support, and minimal handling.
Consider withholding supplemental oxygen based on guideline-specific thresholds: the AAP allows withholding above 90%; the Australasian guideline uses a target of ≥92%; and NICE (2021) uses a tiered system — give oxygen if SpO2 is persistently below 90% for children aged 6 weeks and over, or below 92% for babies under 6 weeks or children of any age with underlying health conditions. Brief, self-resolving desaturations during sleep are common and do not require treatment. The threshold for supplemental oxygen varies across guidelines, but the direction of travel is towards accepting lower saturations to avoid unnecessary treatment.
Conditional Rec Low Evidence AAP 2014 NICE 2021 Australasian 2025Consider using intermittent rather than continuous pulse oximetry in hospitalised infants who are clinically stable and not receiving supplemental oxygen. A randomised trial demonstrated that intermittent monitoring shortened hospital stay without increasing adverse events.
Conditional Rec Low Evidence AAP 2014 Australasian 2025Administer nasogastric or intravenous fluids for infants who cannot maintain adequate oral hydration. Nasogastric feeding is generally preferred over IV fluids as it maintains enteral nutrition and is less invasive. Consider small frequent feeds and offer feeds during the less symptomatic phase of the illness.
Strong Rec Low Evidence AAP 2014 NICE 2021Perform gentle superficial nasal suctioning before feeds and when secretions are visibly obstructing the airway. Avoid deep nasopharyngeal suctioning, which causes mucosal trauma and oedema and may worsen obstruction.
Moderate Rec Low Evidence CPS 2021 Australasian 2025Clinical Decision Pathway
Evidence in Context
Where All Four Guidelines Agree
The AAP (2014), NICE (2021), CPS (2021), and Australasian (2025) guidelines are remarkably aligned on core management. All four agree that bronchiolitis is a clinical diagnosis, routine investigations are unnecessary, bronchodilators and corticosteroids are ineffective, antibiotics should be withheld, and supportive care (oxygen, hydration, minimal handling) is the standard of treatment. This level of international consensus is unusual in paediatrics.
Where the Guidelines Differ: Oxygen Thresholds
The most clinically significant difference is the SpO2 threshold for supplemental oxygen. The AAP allows withholding oxygen above 90%. NICE (2021 update) uses a tiered system: give oxygen if SpO2 is persistently below 90% for children aged 6 weeks and over, or below 92% for babies under 6 weeks or children with underlying health conditions. The Australasian guideline uses a target of SpO2 ≥92%. The CPS recommends oxygen for persistent SpO2 below 90%. A lower threshold means fewer infants receive oxygen and potentially shorter hospitalisations, but requires confidence that transient desaturations are benign. In practice, clinical judgement should interpret any threshold alongside the infant's overall clinical trajectory.
Nebulised Hypertonic Saline: The Ongoing Debate
The AAP states that nebulised hypertonic saline should not be used in the ED but may be considered for hospitalised infants. The Australasian 2025 guideline recommends against routine use in both settings. Early studies suggested benefit in reducing length of stay, but larger subsequent trials have been inconsistent. The current consensus is that if hypertonic saline is used at all, it should be limited to hospitalised infants and not relied upon as a primary therapy.
Combined Steroid + Epinephrine in Severe Bronchiolitis: Emerging Research
A recent ICU-based study suggested that combining dexamethasone with nebulised adrenaline may reduce illness severity in critically ill infants. Further multicentre trials are underway in Canada, Australia, and New Zealand to determine whether this combination reduces hospitalisation in milder disease. Until results are available, this approach is experimental and should not change standard practice for mild-to-moderate bronchiolitis.
What We Still Don't Know
References
- 1.Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis. Pediatrics. 2014;134(5):e1474–e1502. doi:10.1542/peds.2014-2742
- 2.National Institute for Health and Care Excellence. Bronchiolitis in children: diagnosis and management. NICE guideline [NG9]. Published June 2015, last updated August 2021. nice.org.uk/guidance/ng9
- 3.Canadian Paediatric Society. Bronchiolitis: recommendations for diagnosis, monitoring and management of children one to 24 months of age. Updated November 2021. cps.ca/en/documents/position/bronchiolitis
- 4.Borland ML, Loveys K, Babl FE, et al. Australasian Bronchiolitis Guideline: 2025 Update. J Paediatr Child Health. 2025;61(8):1197–1215. doi:10.1111/jpc.70144
- 5.Dalziel SR, Haskell L, O'Brien S, et al. Bronchiolitis. Lancet. 2022;400(10349):392–406. doi:10.1016/S0140-6736(22)01016-9
How to Read the Evidence Tags
Every recommendation carries two tags. These are Medaptly's own simplified interpretations for educational clarity.
Recommendation Strength
| Tag | Meaning | In Practice |
|---|---|---|
| Strong Rec | Benefits clearly outweigh risks. | Standard practice. |
| Moderate Rec | Evidence favours benefit; some uncertainty. | Most patients should receive this. |
| Conditional Rec | Depends on individual circumstances. | Shared decision-making. |
| Against | No benefit or risks outweigh benefits. | Avoid this intervention. |
Evidence Quality
| Tag | Meaning | Confidence |
|---|---|---|
| High Evidence | Multiple RCTs or high-quality meta-analyses. | Very confident. |
| Moderate Evidence | Single RCT or large observational studies. | Reasonably confident. |
| Low Evidence | Expert consensus or small studies. | Less certain; best available guidance. |
For full classification systems, consult the original documents in References.